由生物技術開發中心獲經濟部科專支持,本土研發的「DCBCI0901」小分子抗癌標靶新藥,研究結果顯示,對肺癌、乳癌、攝護腺癌皆具明顯抑制癌細胞生長活性,為推動此一本土抗癌新藥商品化,由生達(1720-TW)、永信(3705-TW)、中化(1701-TW)以及健喬集團(4114-TW)旗下益得等4大藥廠攜手,透過授權方式與生技中心共組專業團隊共同開發此一新藥,目前已分別通過美國食品暨藥物管理局(FDA)與我國衛生福利部食品藥物管理署(TFDA)之人體臨床試驗階段(Investigational New Drug, IND)申請,獲准進入第一期人體臨床試驗。
This entry passed through the Full-Text RSS service — if this is your content and you're reading it on someone else's site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.
You are receiving this email because you subscribed to this feed at blogtrottr.com.